SPECIAL NOTICE
A -- Autoinjectors Containing Midazolam
- Notice Date
- 7/6/2018
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - APG (W911QY) Natick (SPS), 10 General Green Avenue, Building 1, Natick, Massachusetts, 01760-5011, United States
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY-18-S-0009
- Archive Date
- 7/24/2018
- Point of Contact
- Richard Totten, Phone: 3016192446
- E-Mail Address
-
richard.w.totten2.civ@mail.mil
(richard.w.totten2.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Contracting Division intends to negotiate and award a Firm Fixed Price, sole source contract to Meridian Medical Technologies Inc., located at 6350 Stevens Forest Road, Columbia, MD 21046. Pursuant to the authority prescribed at 10 U.S.C. § 2304(c)(1) and Federal Acquisition Regulation 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. This acquisition requires the manufacture and delivery of 90,000 Food and Drug Administration approved autoinjectors containing the active ingredient Midazolam. Meridian Medical Technologies (MMT) is currently under contract with the Joint Product Management Office - Joint Product Manager - Medical Countermeasure Systems (JPMO-JPM-MCS) for the development of an FDA approved autoinjector for the treatment of seizures, under contract W9113M07-C-0159. This ACAT III program was established by JPEO-CBRND to develop an alternative treatment to replace the currently fielded CANA autoinjector containing Diazepam. The contract currently requires the delivery of Initial Operation Capability (IOC) and Full Operational Capability (FOC) autoinjectors. This requirement increases the deliverable FOC by 90,000. Responders are encouraged to address their abilities to perform the requirements and accessibility to the necessary data within 15 days of this notice. This is a modification to an existing contract. MMT currently holds the Investigational New Drug application for an autoinjector containing the Midazolam, and is under contract to obtain FDA approval of a New Drug Application (NDA). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. This special notice is not a request for competitive proposals however, responsible parties purporting to have the necessary qualifications with the ability to meet this requirement must submit official documentation to this fact. Submission instructions are provided below. The Government will retain comments and information received in response to this Special Notice. Proprietary information should be identified as Company Proprietary. Do not use Government Security classification markings. Questions regarding this Special Notice should be emailed to the point of contact listed below. All written responses must be received no later than 23 Jul 2018. Submissions shall be electronic only and: (1) use Microsoft Word or Adobe Portable Document Format (PDF); (2) be sent to the Point of Contact email below. Material considered advertisement is not desired. Contracting Office Address: Army Contracting Command, Aberdeen Proving Ground, Natick Division 110 Thomas Johnson Dr, Frederick, MD 21702 Point of Contact(s): Richard Totten, Contracting Officer Richard.w.totten2.civ@mail.mil
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/697c22f1f385b344993888deb0faec9e)
- Record
- SN04982115-W 20180708/180706230638-697c22f1f385b344993888deb0faec9e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |